SOURCE: Novo Nordisk A/S

February 15, 2010 08:41 ET

Transaction in Own Shares

BAGSVAERD, DENMARK--(Marketwire - February 15, 2010) -



Novo Nordisk A/S - Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010.


Since the announcement as of 8 February 2010, the following transactions have been made under the programme:

                      Number of shares Average purchase  Transaction value,
                                               price                   DKK

Accumulated, last             435,000                         162,272,753
 announcement

08 February 2010               90,000          373.8999        33,650,991

09 February 2010               90,000          374.0000        33,660,000

10 February 2010               90,000          374.0290        33,662,610

11 February 2010               90,000          378.7490        34,087,410

12 February 2010               90,000          385.0110        34,650,990

Accumulated under the         885,000                         331,984,754
 programme

Transactions related to Novo Nordisk's incentive programmes have resulted in a net sale by Novo Nordisk of 359,222 B shares in the period from 8 February 2010 to 12 February 2010. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 31,281,948 treasury shares, corresponding to 5.0% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.


Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:


 Media:                                  Investors:


 Elin K Hansen                           Klaus Bulow Davidsen
 Tel: (+45) 4442 3450                    Tel: (+45) 4442 3176
 ekh@novonordisk.com                     klda@novonordisk.com


                                         Kasper Roseeuw Poulsen
                                         Tel: (+45) 4442 4471
                                         krop@novonordisk.com


In North America:                        In North America:
Sean Clements                            Hans Rommer
Tel: (+1) 609 514 8316                   Tel: (+1) 609 919 7937
secl@novonordisk.com                     hrmm@novonordisk.com

Company Announcement no 9 / 2010


[HUG#1384418]

Company Announcement no 9 2010: http://hugin.info/2013/R/1384418/343190.pdf

Contact Information